A role for macrophages in erythropoiesis was suggested several decades ago when erythroblastic islands in the bone marrow, composed of a central macrophage surrounded by developing erythroblasts, were described. However, the in vivo role of macrophages in erythropoiesis under homeostatic conditions or in disease remains unclear. We found that specific depletion of CD169 + macrophages markedly reduced the number of erythroblasts in the bone marrow but did not result in overt anemia under homeostatic conditions, probably because of concomitant alterations in red blood cell clearance. However, CD169 + macrophage depletion significantly impaired erythropoietic recovery from hemolytic anemia, acute blood loss and myeloablation. Furthermore, macrophage depletion normalized the erythroid compartment in a JAK2 V617F -driven mouse model of polycythemia vera, suggesting that erythropoiesis in polycythemia vera remains under the control of macrophages in the bone marrow and splenic microenvironments. These results indicate that CD169 + macrophages promote late erythroid maturation and that modulation of the macrophage compartment may be a new strategy to treat erythropoietic disorders. npg
Humans produce millions of erythrocytes each minute, and careful coordination of their production and clearance is crucial to maintain erythropoietic homeostasis. This homeostasis can be challenged by a variety of perturbations: genetic (for example, sickle cell disease, thalassemia or polycythemia vera), infectious (for example, malaria or parvovirus), exposure (for example, lead, radiation or traumainduced blood loss) and iatrogenic (for example, chemotherapy or bone marrow transplant).
In 1958, Marcel Bessis proposed that erythropoietic maturation required a specific microenvironment comprising a nursing macrophage decorated by erythroblasts at various stages of maturation, culminating in enucleation 1 . A functional role for these erythroblastic islands was first demonstrated by Narla and colleagues, who showed that hypertransfused rats had a substantial reduction in the number of islands as quantified by tridimensional electron microscopy 2 . A supportive role of macrophages in erythroblast development was strengthened by in vitro observations that macrophages promote erythroblast proliferation and survival [3] [4] [5] , and an extensive amount of work has been done to characterize the adhesive interactions within these islands (reviewed in ref. 6) . Nonetheless, whether macrophages contribute to erythropoiesis in vivo remains to be elucidated.
We have recently reported that mouse bone marrow macrophages express CD169 (also known as Sialoadhesin or Siglec-1) 7, 8 and that these macrophages can be selectively depleted in CD169-DTR mice, which express the human diphtheria toxin receptor (DTR) knocked in downstream of the endogenous Siglec1 promoter 9 . As central macrophages in erythroblastic islands reportedly express CD169 (ref. 10) , we re-examined the role of macrophages in steady-state erythropoiesis in vivo. Moreover, we assessed the contribution of bone marrow and splenic macrophages to recovery from erythropoietic stress and also to the hyperfunctional erythron observed in a JAK2 V617F -driven mouse model of polycythemia vera.
RESULTS

CD169 + macrophages promote bone marrow erythropoiesis
To examine the role of bone marrow macrophages in erythroblast formation, we used heterozygous CD169-DTR (CD169 DTR/+ ) mice. We found that after sustained diphtheria toxin administration and ensuing depletion of bone marrow CD169 + macrophages but not monocytes 7, 8 , the long bones of the CD169 DTR/+ mice were paler than those of wild-type (WT) control mice ( Fig. 1a) , which was associated with a >60% reduction in the number of F4/80 + Ter119 + erythroblast islands ( Fig. 1b and Supplementary Fig. 1 ). Using two gating schemes, we also found that sustained depletion of CD169 + macrophages (Fig. 1c) reduced the number of erythroblasts in the bone marrow at various time points after initiation of depletion, starting as early as 12 h after diphtheria toxin administration Fig. 1c-e and Supplementary  Fig. 2a,b) . We observed this reduction in the number of bone marrow erythroblasts across all stages of maturation ( Supplementary  Fig. 2c-e ). Cultured erythroblasts from CD169 DTR/+ mice were unaffected by diphtheria toxin administration ( Supplementary  Fig. 2f,g) , whereas cultured macrophages were susceptible at the same dose (ref. 7 and data not shown), ruling out a direct depletion of erythroblasts. Consistent with the flow cytometry data, we found a ~50% reduction in the number of erythroid colony forming units (CFU-E), but not erythroid blast forming units (BFU-E), in the bone marrow 24 h after diphtheria toxin administration ( Supplementary  Fig. 2h,i) . These results are consistent with the notion that macrophages are important for bone marrow erythroblast development starting with the CFU-E or proerythroblast stage 6, 11 . The reduction in the number of erythroblasts was not the result of decreased cell proliferation or viability (Supplementary Fig. 3) .
Our recent observation that CD169 + macrophages control the retention of hematopoietic stem and progenitor cells in the bone marrow 7 together with our finding that the reduction in the number of bone marrow CD169 + macrophages and erythroblasts follow similar kinetics in the CD169 DTR/+ depletion model ( Fig. 1c,e ) led us to hypothesize that increased release of erythroblasts into the peripheral circulation might account for the erythroblast reduction in the bone marrow. Indeed, 24 h after initiation of CD169 + macrophage depletion, we found a greater than twofold increase in the number of erythroblasts in the peripheral blood ( Supplementary Fig. 4a,b) , consistent with a previous report 12 . Although peripheral blood erythroblasts were similarly viable ( Supplementary Fig. 4c ), they proliferated half as much as their bone marrow counterparts ( Supplementary Fig. 4d ). This increased concentration of circulating peripheral erythroblasts was sustained after 4 weeks of depletion, and the concentrations of all four subsets of erythroblasts were increased ( Supplementary  Fig. 4e-i) . As the spike in the concentration of peripheral blood erythroblasts alone cannot account for the reduction of their numbers in the bone marrow, the erythroblasts were presumably mobilized to the spleen ( Supplementary Fig. 5d ,e) and to other unexamined peripheral tissues. Thus, although bone marrow CD169 + macrophages do not regulate erythroblast proliferation or viability per se in the steadystate bone marrow, they do control their retention in the bone marrow, which is a major site for erythropoiesis.
Despite a reduction in the number of bone marrow erythroblasts, CD169 + macrophage-depleted mice did not develop an overt peripheral blood anemia ( Fig. 1f) , consistent with previous reports using clodronate liposomes to deplete macrophages 12, 13 . CD169 + macrophage-depleted mice did not have a compensatory increase in serum erythropoietin (EPO) concentration or in hepatic erythroblastosis (Supplementary Fig. 5a-c) . Although compensatory splenic erythroblastosis was present, splenectomized CD169 + macrophage-depleted mice did not develop overt anemia, indicating that splenic compensation was not solely responsible for masking the bone marrow production deficit ( Supplementary Fig. 5d-f ). Along with bone marrow macrophages, the numbers of splenic red pulp macrophages (RPM) and hepatic Kupffer macrophages were reduced after 4 weeks of sustained diphtheria toxin administration ( Supplementary Fig. 5g-i) . Consistent with the latter two cell populations being crucial for the clearance of aged red blood cells (RBCs) 14 , we found that CD169 + macrophage depletion resulted in a ~25% increase in RBC lifespan after 4 weeks, suggesting that abrogated clearance of aged RBCs was a mechanism parallel to splenic compensation that masked the reduction in the number of bone marrow erythroblasts in the steady state ( Fig. 1g,h) . We used mathematical modeling to assess whether the prolongation of RBC lifespan was sufficient to explain the absence of anemia after macrophage depletion. Because macrophages were involved in both the npg production and clearance of RBCs, the analysis suggested that peripheral RBC counts in the steady state are proportional to the ratio between the rates of production and clearance and are independent of absolute macrophage content ( Supplementary Fig. 6 ).
Macrophages are crucial for recovery from acute anemia Although no anemia developed after CD169 + macrophage depletion in mice at steady state, we reasoned that macrophages might have a more prominent role during erythropoietic stress. Indeed, in a model of hemolytic anemia induced by the hemoglobin-oxidizing toxin phenylhydrazine (PHZ), we observed a delay in reticulocytosis and hematocrit recovery in macrophage-depleted mice using either the CD169-DTR model or clodronate liposome administration, which depletes most mononuclear phagocytes, including bone marrow monocytes and CD169 + macrophages 7 ( Fig. 2a-d) .
Clodronate liposomes impaired recovery from hemolytic anemia to a greater extent than in the CD169-DTR model, and we reasoned that this could be due to the differential capacities of the two models to deplete splenic RPM. Indeed, whereas both models efficiently depleted bone marrow macrophages 7 , short-term administration of diphtheria toxin did not result in a reduction in splenic RPM ( Supplementary  Fig. 7a ). This result is consistent with a previous report 9 and in contrast to the reduction in splenic RPM observed after 4 weeks of diphtheria toxin administration ( Supplementary Fig. 5h ). Pretreatment with clodronate liposomes 5 d before the administration of PHZ reduced macrophage numbers and impaired the recovery of erythroblasts in the bone marrow and spleen ( Supplementary  Fig. 7b-e ). Moreover, macrophage depletion reduced the induction of splenic bone morphogenic protein 4 (BMP4) and the number of splenic-stress BFU-E ( Supplementary Fig. 7f,g) . The impairment in hematocrit recovery from PHZ challenge in CD169 DTR/+ mice, which did not have splenic RPM depletion after short-term diphtheria toxin administration, suggested that bone marrow erythropoiesis functionally contributes to recovery from hemolytic anemia. To further ascertain the contribution of bone marrow erythropoiesis to erythroid recovery after PHZ challenge, we compared recovery of control splenectomized and CD169 + macrophage-depleted splenectomized mice. The erythroid recovery from PHZ challenge of splenectomized mice was slower compared to nonsplenectomized mice; moreover, splenectomized CD169 + macrophage-depleted mice showed a hampered recovery compared to splenectomized nondepleted control mice, indicating the independent contribution of bone marrow macrophages to erythroid reconstitution in the setting of hemolytic anemia ( Fig. 2b ,e,f ). Consistent with the results from the PHZ model and with a previous report 15 , macrophage-depleted mice also showed a substantial impairment in recovery from acute blood loss compared to nondepleted mice ( Fig. 2g,h) . Therefore, in two models of acute RBC reduction, macrophages are essential for efficient erythroid recovery.
Splenic RPM are crucial for erythroid recovery after myeloablation
To test whether CD169 + macrophages also contribute to erythroid recovery from myeloablation, we depleted CD169 + macrophages in mice after bone marrow transplantation (BMT). BMT itself reduced the number of bone marrow CD169 + macrophages and erythroblasts 7 d after BMT ( Fig. 3a,b) , and the reduction in the number of erythroblasts was even more pronounced when CD169 + macrophages were depleted after BMT ( Fig. 3b) . Moreover, CD169 + macrophage depletion after BMT severely abrogated the recovery of splenic erythroblasts ( Fig. 3c,d) . Thus, in the context of myeloablation, splenic RPM are efficiently depleted by short-term diphtheria toxin administration in the CD169-DTR model. CD169 + macrophage depletion also delayed reticulocytosis and hematocrit recovery ( Fig. 3e,f) , indicating the functional peripheral consequences of impaired erythroblast recovery. CD169 + macrophage depletion was similarly associated with delayed erythroblast and peripheral erythrocyte recovery after challenge with the myeloablative agent 5-fluorouracil (5FU) ( Supplementary Fig. 8a-g) . Notably, in both the BMT and 5FU models, CD169 + macrophage-depleted mice had less severe early declines in hematocrit ( Fig. 3f and Supplementary Fig. 8g ). This result suggests that myeloablation-induced pathogenic consumption of mature RBCs by macrophages may contribute to anemia after clastogenic injury. We verified this hypothesis by observing that RBCs had a longer half-life in CD169 + macrophage-depleted mice shortly after BMT (Supplementary Fig. 8h ). Together these results indicate that similarly to the case in the steady state, CD169 + macrophages promote both the production and destruction of erythrocytes after myeloablation. Notably, in the setting of myeloablative stress, the supportive role of CD169 + macrophages in erythroid production is dominant over its concomitant role in clearance. npg It was initially hypothesized that macrophages may be nurse-like cells that provide iron to developing RBCs 1 , and macrophage regulation of iron homeostasis has subsequently been well documented 16 . We analyzed serum iron, transferrin saturation, mean corpuscular hemoglobin (MCH) and reticulocyte hemoglobin content (CHr) in the steady state or after BMT to evaluate the potential effect of CD169 + macrophage depletion on iron homeostasis in erythrocytes. In the steady state, CD169 + macrophage depletion reduced serum iron concentration, transferrin saturation, MCH and CHr after 3-4 weeks of sustained depletion (Supplementary Fig. 9a-d) . This delayed effect is more consistent with compromised ferroportin-mediated systemic iron recycling by macrophages 17 rather than with a local nurse-like cell function. In the context of erythropoietic challenge from BMT, we did not observe any statistically significant changes in serum iron concentration or transferrin saturation 7 d after transplant, and there was no reduction in MCH until the third week after BMT. However, we found a reduction in CHr by 7 d after BMT (Supplementary Fig. 9e-h) , suggesting a local role of tissue macrophages in iron homeostasis in the early recovery from myeloablation, consistent with a local nurse-like cell role. Systemic administration of iron dextran did not rescue the impaired erythropoietic recovery in CD169 + macrophage-depleted mice ( Supplementary Fig. 9i,j) . Although these data do not preclude a local role for macrophages in providing iron to the developing RBCs, they suggest that macrophages alter the erythron through additional mechanisms. i j npg As BMP4 promotes the development of stress erythroid progenitors after BMT 18, 19 , we assessed whether induction of splenic BMP4 was reduced in CD169 + macrophage-depleted mice after BMT. Indeed, we found that splenic induction of BMP4 and stress BFU-E was abrogated in these mice (Fig. 3g,h) . Splenic RPM are radioresistant compared to other hematopoietic populations 20, 21 and have been previously implicated as the source of BMP4 (ref. 22) . As 90% of splenic RPM were of host origin 7 d after BMT ( Supplementary  Fig. 9k ), we assessed whether depletion of host-derived splenic RPM was sufficient to abrogate erythropoietic recovery by performing reciprocal BMT between WT and CD169 DTR/+ mice, followed by treatment of all sets of transplanted mice with diphtheria toxin. WT mice transplanted with CD169 DTR/+ bone marrow cells (DTR→WT) showed comparable numbers of macrophages and erythroblasts to WT→WT mice 7 d after BMT, consistent with the minimal donor reconstitution of RPM at this time point (Fig. 3i,j) . CD169 DTR/+ mice transplanted with WT bone marrow cells (WT→DTR) showed similar amounts of depletion of splenic RPM compared to CD169 DTR/+ mice transplanted with CD169 DTR/+ bone marrow cells (DTR→DTR), confirming the predominance of host-derived RPM 7 d after BMT (Supplementary Fig. 9l) . Notably, WT→DTR mice had impaired recovery of splenic erythroblasts and stress BFU-E (Fig. 3i,j) . Taken together, these results show that BMP4 derived from radioresistant, host-derived splenic RPM is crucial for erythroid recovery after myeloablation.
VCAM1 promotes erythropoietic recovery after myeloablation
Vascular cell adhesion molecule 1 (VCAM1) has previously been demonstrated to have a role in erythroblast island interactions in vitro 23 . Gene expression profiling of purified bone marrow mononuclear phagocytes revealed that the expression of Vcam1 transcripts was higher in bone marrow CD169 + macrophages compared to bone marrow Gr1 hi or Gr1 lo monocytes (Supplementary Fig. 10a ). 24 had abundant expression of VCAM1 ( Fig. 4a and Supplementary Fig. 10b) . In addition, cell-surface expression of VCAM1 was reduced in the bone marrow of CD169 + macrophage-depleted mice in the steady state (Supplementary Fig. 10c ) and at 7 d after BMT (Fig. 4b) . In line with the role of radioresistant host-derived macrophages in the spleen, we also found substantial radioresistance of bone marrow macrophages 7 d after BMT (Supplementary Fig. 10d) . Moreover, depletion of host-derived bone marrow CD169 + macrophages in the reciprocal BMT model was sufficient to reduce the number of CD169 + macrophages, the expression of VCAM1 and the number of erythroblasts in the bone marrow ( Fig. 4c-e) . Notably, antibody to VCAM1 administered after BMT in macrophage-sufficient mice led to impaired recovery of bone marrow erythroblasts, reticulocytes and hematocrit ( Fig. 4f-h) , similarly to the effects seen in macrophagedepleted mice. Splenic VCAM1 expression was not markedly reduced by CD169 + macrophage depletion, and antibody to VCAM1 did not abrogate the development of splenic erythropoiesis ( Supplementary  Fig. 10e,f) . These data suggest that VCAM1 expressed by CD169 + bone marrow macrophages works in parallel with BMP4 derived from CD169 + splenic macrophages to promote erythroid recovery after myeloablation.
Monocytes had low expression of VCAM1 on the cell surface, whereas both bone marrow and splenic RPM
To determine whether human bone marrow macrophages share features with their mouse counterparts, we performed phenotypic analysis of cells from the bone marrow aspirate of healthy donors and assessed them for CD169 and VCAM1 expression. CD15 is a marker of human granulocytes and monocytes 25 (Fig. 5a,b) , and neither CD15 + CD14 − granulocytes nor CD15 + CD14 + monocytes expressed CD169 or VCAM1. CD163 is a marker of human monocytes and macrophages 26 . Within the CD15 − CD163 + cell population, a CD169 + VCAM1 + cell population with macrophage morphology was present (Fig. 5a,b and Supplementary Fig. 10g ), whereas the CD169 − VCAM1 − cell population had a monocytic morphology. Therefore, similar to their mouse counterparts, human bone marrow macrophages can also be identified by CD169 and VCAM1 expression.
Macrophage depletion normalizes polycythemia vera
Having demonstrated the role of macrophages in recovery after erythropoietic insufficiency, we next tested whether macrophage depletion could be beneficial in the context of an overactive erythron in a mouse model of polycythemia vera. We hypothesized that even when driven by an oncogenic mutation, erythropoiesis might still respond to microenvironmental cues from its niche. We transplanted bone marrow cells isolated from WT mice or transgenic mice harboring the JAK2 V617F mutation 27 into lethally irradiated WT mice. We observed increased reticulocytosis by day 9 after BMT ( Fig. 6a) and erythrocytosis by day 16 (Fig. 6b and Supplementary  Fig. 11a) , whereas white blood cell and platelet recovery were not consistently different (Supplementary Fig. 11b,c) . Five weeks after BMT, recipients of JAK2 V617F bone marrow (polycythemia vera mice) were infused once weekly with PBS-or clodronate-encapsulated liposomes for 4 weeks. Macrophage depletion reduced the number of erythroblasts in the bone marrow and spleen ( Fig. 6c-f) , affecting all splenic erythroblast subsets (Supplementary Fig. 11d-g) , and normalized blood hematocrit (Fig. 6g) . The therapeutic benefit of macrophage depletion persisted for 4 weeks after the cessation of liposome treatment (Fig. 6g) . A single administration of clodronate liposomes was sufficient to reduce the number of macrophages and erythroblasts in the bone marrow and spleen (Supplementary Fig. 11h-k) and normalized the hematocrit for a shorter period than did administration of 4 weekly doses (Supplementary Fig. 11l ).
In the polycythemia vera model, macrophage depletion had a subtle effect on MCH, serum iron and transferrin saturation but a rapid effect on CHr (Supplementary Fig. 12a-d) . Although treatment of polycythemia vera mice with the iron-chelating agent deferoxamine reduced serum iron concentrations (Supplementary Fig. 12c) , it reduced neither splenic erythroblast numbers nor hematocrit (Supplementary Fig. 12e,f) . Hence, global alterations in iron are not the mechanism by which macrophage depletion suppresses polycythemia vera, although this does not necessarily rule out a local microenvironmental effect.
Because splenic erythropoiesis was reduced by macrophage depletion, we hypothesized that the JAK2 V617F mutation could potentially induce splenic stress erythropoiesis. Consistent with this hypothesis, we found induction of BMP4 and stress BFU-E in polycythemia vera mice (Fig. 6h,i) and, notably, clodronate treatment abrogated this induction (Fig. 6h,i) . We also found that the number of EPO-independent endogenous erythroid colonies, a clinical criterion of JAK2 V617F -driven polycythemia vera 28 , was markedly driven after macrophage depletion ( Fig. 6j  and Supplementary Fig. 12g) . These results suggest that therapies targeting macrophages may represent a new strategy for the management of polycythemia vera.
DISCUSSION
Although erythroblastic islands were the first hematopoietic niche to be described, the in vivo relevance of this microenvironment for developing RBCs has been unclear. In this study we provide evidence for a dual role of tissue resident macrophages in both RBC production and clearance. Although these antagonistic roles offset in the steady state, we demonstrate that the supportive role of macrophages in RBC development is dominant in recovery from hemolytic anemia, acute blood loss, myeloablation and JAK2 V617F -induced polycythemia vera.
The delay in erythroid progenitor recovery from hemolytic anemia observed in macrophage-depleted mice is consistent with the impaired recovery previously reported in Mx1-Cre; Itga4 flox/flox , Mx1-Cre; Itgb1 flox/flox and Tie2-Cre; Vcam1 flox/flox mice [29] [30] [31] . Our results together with these previous findings indicate that binding of erythroblast integrins to VCAM1 on the central macrophage surface promotes recovery from hemolytic anemia. However, despite the delay in erythroid progenitor recovery, defects in erythroid integrins 30, 31 do not affect peripheral erythrocyte recovery from hemolytic anemia to the same extent that macrophage depletion does, suggesting additional adhesion-independent mechanisms.
In the myeloablative setting, we found that depletion of radioresistant host-derived CD169 + macrophages impaired recovery of bone marrow and splenic erythroblasts, results which are in line with the tight correlation between the recovery rates of macrophages and erythroid progenitors after allogeneic BMT in humans 32, 33 . Antibody blockade of VCAM1 was able to reproduce the delayed bone marrow erythroblast recovery observed in CD169 + macrophage-depleted mice, implicating the importance of VCAM1 on the surface of CD169 + macrophages npg in promoting erythroblast recovery after BMT. Human CD169 has a sequence similarity of 72% compared to the mouse protein and is found on human bone marrow-resident, splenic red-pulp and liver macrophages 34 . Here we report that coexpression of CD169 and VCAM1 can be found in a population of CD15 − CD163 + cells with macrophage morphology in human bone marrow aspirates, indicating the presence of a macrophage population in humans similar to that found in mice. Subsequent studies will elucidate whether these human CD169 + macrophages share other properties with their mouse counterparts. Stress erythropoiesis in mice is dependent on BMP4, which works in concert with stem cell factor, EPO and hypoxia signals 19 . Flextailed mice, which have a mutation in the BMP4 downstream target SMAD5, have impaired development of stress erythroid progenitors 35 and show severe impairment in peripheral erythroid recovery from hemolytic anemia 36 . We found that clodronate liposome pretreatment impairs BMP4 induction, delays development of stress BFU-E and severely compromises peripheral erythroid recovery from hemolytic anemia, consistent with the requirement of macrophages to mount BMP4-mediated stress erythropoiesis. We also found that depletion of CD169 + macrophages after BMT abrogated the development of BMP4-dependent stress erythropoiesis in the spleen. The finding that CD169 + macrophage-depleted mice phenocopy the erythroidspecific impairment in recovery after BMT reported in flex-tailed mice 18, 19 suggests that BMP4 derived from splenic RPM 22 promotes stress erythropoiesis in the spleen. Taken together, these data support a model in which VCAM1 expressed by host-derived bone marrow CD169 + macrophages and BMP4 expressed by host-derived splenic RPM work in concert to mediate erythrocyte recovery after myeloablation. Persistent anemia after clinical hematopoietic stem cell transplant is a serious concern that currently has no optimal solutions 37, 38 . Blood transfusions are associated with iron overload and increased risk of infection, and erythropoietin supplementation does not reduce the number of transfusions required 39 . Thus, strategies to boost CD169 + macrophage recovery after chemotherapy or irradiation-induced injury may be a new approach to potentially accelerate recovery of the RBC compartment after transplant.
In contrast to myeloablated individuals, patients with polycythemia vera have a hyperfunctional erythron, resulting in increased blood viscosity and a substantial incidence of thrombosis 40 . The current standard-of-care treatment for patients with polycythemia vera is phlebotomy 40 . JAK2 inhibitors to suppress polycythemia vera are under clinical trials but are limited by dose-dependent toxicity and there is also evidence that resistance can develop 41 . In a mouse model of polycythemia vera, we found that macrophage depletion could normalize the expanded erythron. To our knowledge, this is the first report showing that BMP4 and stress erythropoiesis contribute to the pathogenesis of polycythemia vera in mice, and we also show that macrophage depletion abrogates this erythroid expansion. Notably, we show that the numbers of EPO-autonomous colonies, a diagnostic criterion of polycythemia vera 28 , were reduced with macrophage depletion. The dependence of polycythemia vera on macrophage function was unexpected, as erythropoiesis in this disease had been thought to proceed cell autonomously. Thus, our data indicate that inhibition of the macrophage compartment (for example, using colony-stimulating factor 1 (CSF-1) inhibitors 42 ) or abrogation of BMP4 activity may point to new avenues for polycythemia vera treatment in addition to phlebotomy and JAK2 inhibitor treatment.
In this study we clarify the dual roles of macrophages in steadystate erythropoiesis and show their importance in hemolytic anemia, acute blood loss, myeloablative injury and polycythemia vera. In an accompanying manuscript, Rivella and colleagues 43 independently reached the same conclusions that macrophages are crucial in erythroblastic expansion in stress erythropoiesis and that macrophage targeting can normalize the erythron in polycythemia vera. Together, these two studies strongly support an in vivo function for the erythroblastic island and offer new opportunities for using this knowledge in the treatment of patients with disorders of erythropoiesis.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Mice.
All experiments were performed on a mix of male and female 8-to 12-week-old mice. C57BL/6 (CD45.2) mice were bred in house or purchased from Charles River Laboratories (Frederick Cancer Research Center, Frederick, Maryland). For experiments using JAK2 V617F mice, C57BL/6-Ly5.2 (CD45.1) mice were purchased from Charles River Laboratories. CD169-DTR 9 heterozygous (CD169 DTR/+ ) mice on a C57BL/6 background, which were generated with DTR complementary DNA 44 , were bred in house by crossing CD169 DTR/DTR mice with C57BL/6 mice. With the exception of the JAK2 V617F mice, which were housed at the University of Oklahoma Health Sciences Center, all other mice were housed in specific pathogen-free facilities at the animal facility of either Mount Sinai School of Medicine or Albert Einstein College of Medicine. Experimental procedures performed on the mice at each site were approved by the Institutional Animal Care and Use Committee of the Mount Sinai School of Medicine or the Albert Einstein College of Medicine.
Macrophage depletion. For depletion of CD169 + macrophages, heterozygous CD169-DTR (CD169 DTR/+ ) mice were injected intraperitoneally with 10 µg per kg body weight diphtheria toxin (Sigma). For steady-state experiments, mice were injected with a single dose of diphtheria toxin or were injected twice weekly for sustained depletion. For PHZ experiments, mice were injected with diphtheria toxin on days -2, 0, 2, 4 and 6 of the experiment (with PHZ administered on days 0 and 1). For the BMT and 5FU experiments, diphtheria toxin was administered every 3 d starting 1 d after BMT or 5FU administration. Neither C57BL/6 mice injected with diphtheria toxin nor CD169 DTR/+ mice not injected with diphtheria toxin demonstrated macrophage depletion and were thus pooled as control (Ctrl) mice. CD169 DTR/+ mice injected with diphtheria toxin served as macrophagedepleted experimental mice (DTR). Analysis of macrophage depletion in the CD169 DTR/+ model beyond 6 weeks is not possible because of the development of immunity to diphtheria toxin (data not shown). In some experiments, macrophages were depleted by injection of PBS-or clodronate-encapsulated liposomes (200 µl intravenous (i.v.) infusion). Dichloromethylene diphosphonate (Cl 2 MDP, also called clodronate) was a gift from Roche Diagnostics (GmbH, Mannheim, Germany). For PHZ and acute bleeding experiments, a single infusion of liposomes was administered on day -5 of the experiment. For polycythemia vera experiments, a single dose (day 0 of the experiment) or four doses (days 0, 7, 14 and 21) were administered as indicated in the text.
Complete blood count analysis. Mice were bled ~25 µl by submandibular route into an Eppendorf tube containing 1 µl of 0.5 M EDTA (Fisher). Blood was diluted 1:10 in PBS and analyzed with an Advia counter (Siemens).
Cell preparation. Nucleated single-cell suspensions were enriched from peripheral blood, bone marrow, spleen and liver by harvesting the interface layer from a lympholyte gradient (Cedar Lane Labs) according to the manufacturer's directions. For peripheral blood, 250-500 µl of peripheral blood was diluted in 2 ml of RPMI media (Cellgro) and carefully pipetted onto 3 ml of lympholyte solution in a 15-ml tube (Falcon). For bone marrow, femurs were flushed gently with 500 µl of ice-cold PBS (Cellgro) through a 1-ml syringe (BD) with a 21G needle (BD) into an Eppendorf tube; the entire solution was then carefully layered onto 1 ml of lympholyte solution in a 5-ml polystyrene tube (BD). Spleens were mashed through a 40-µm filter (BD) onto a six-well plate (BD) containing 4 ml of ice-cold PBS. The cell suspension was resuspended to approximately 20 × 10 6 cells per ml, and 500 µl was layered onto 1 ml of lympholyte solution in a 5-ml polystyrene tube (BD). Liver cells were mechanically diced and digested in a RPMI media (Cellgro) solution containing 0.4 mg/ml type IV collagenase (Sigma) and 10% FBS (Stem Cell Technologies) for 1 h. The liver suspension was drawn through a 3-ml syringe (BD) with a 19G needle (BD) and filtered through a 40-µm filter (BD). The cells were resuspended in 1 ml PBS and centrifuged on a 30% Percoll gradient. The supernatant was discarded and the pellet was resuspended in 500 µl and layered onto 1 ml of lympholyte solution in a 5-ml polystyrene tube (BD). For FACS analyses, RBC lysis with ammonium chloride was not used, as some erythroblasts became DAPI + after lysis.
In vivo isolation of erythroblast islands. The protocol used was modified from ref. 3 . Bone marrow was flushed gently with Iscove's modified Dulbecco's medium (Cellgro) containing 3.5% sodium citrate and 20% FCS solution using an 18G syringe (BD). After pipetting 20 times, 8% of the bone marrow by volume (~1 × 10 6 cells) was incubated with antibodies to F4/80-fluorescein isothiocyanate (FITC, clone BM8) and Ter119-phycoerythrin (PE, clone TER-119) at 1:100 for 2 h at room temperature. Cells were then diluted 3.5-fold in FACS buffer containing DAPI and processed by flow cytometry or flow sorted for the F4/80 + Ter119 + multiplet population by BD FACSAria. Images of erythroblast islands were acquired from glass slides containing 10,000 islands cytospun at 500 r.p.m. for 3 min with a Cytospin 4 (Thermo Scientific).
Flow cytometry. Fluorochrome-conjugated or biotinylated monoclonal antibodies specific to mouse Gr1 (Ly6C/G) (clone RB6-8C5), CD115 (clone AFS98), B220 (clone RA3-6B2), VCAM1 (clone 429), CD11b (clone M1/70), CD45 (clone 30-F11), CD45.1 (clone A20), CD45.2 (clone 104), Ter119 (clone TER-119), CD71 (clone R17217) and CD44 (clone IM7), the corresponding isotype control antibodies and the secondary reagents (PerCP-eFluor710 and PE-Cy7-conjugated streptavidin) were purchased from Ebioscience. Antibody to F4/80 (clone CI:A3.1) was purchased from AbD Serotec. Primary antibodies were used at 1:200 concentration, whereas secondary antibodies were used at 1:400 concentration. BrdU incorporation of erythroblasts was assessed in mice injected with 100 µg of BrdU intraperitoneally 1 h before harvest, and samples were processed according to the manufacturer's directions in the APC BrdU Kit (BD Biosciences). In some experiments, allophycocyanin (APC)conjugated antibody to BrdU (clone Bu20a) from Biolegend was used. Positive staining was gated in reference to cells from mice that were not injected with BrdU. Viable cells were assessed by double-negative staining of DAPI (1 mg/ml solution diluted to 1:20,000) and annexin V (BD Biosciences). Samples were processed according to the manufacturer's directions, but DAPI was substituted for propidium iodide. In some experiments, Alexa Fluor 647 annexin V was used according to the manufacturer's instructions (Biolegend). For nuclear staining in nonpermeabilized cells, cell suspensions were incubated 1:1,000 with 10 mg/ml Hoechst 33342 solution (Sigma) for 45 min at 37 °C after cellsurface staining with other antibodies. For human bone marrow characterization, antibodies to the following human proteins were used: VCAM1-PE (clone STA, Biolegend), CD169-Alexa 647 (clone 7-239, Biolegend), CD163biotin (clone eBioGHI/61, Ebioscience), CD15-PerCP-eFluor710 (clone MMA, Ebioscience) and CD14-eFluor450 (clone 61D3, Ebioscience, Biolegend). Multiparameter analyses of stained cell suspensions were performed on an LSR II (BD) and analyzed with FlowJo software (Tree Star). DAPI − single cells were evaluated for all analyses except for peripheral blood erythroblasts and BrdU assessments.
In vitro culture of erythroblasts. DAPI − CD11b − CD45 − Ter119 + CD71 + erythroblasts from WT or CD169 DTR/+ mice were sorted by FACS Aria (BD) and cultured for 24 or 48 h, as previously described 45 , at a concentration of 1 × 10 5 sorted cells per 100 µl in a 96-well plate (BD). Some wells were incubated with 1 µg/ml diphtheria toxin. At 24 and 48 h after culture, cells were counted and assessed for viability by annexin − DAPI − staining.
Splenectomy. Mice were splenectomized as previously described 46 and allowed to recover for at least 2 weeks before the onset of experiments. Serum erythropoietin. Serum was frozen and assessed by serum EPO ELISA kit (R&D) according to the manufacturer's directions.
In vivo biotinylation assay. Mice were injected i.v. with 100 mg per kg body weight NHS sulfo-biotin (Thermo Scientific-Pierce) on day 0, and the lifespan of RBCs was assessed weekly 47 by staining 1 µl of peripheral blood with streptavidin-PE-Cy7 and gating CD11b − CD45 − Ter119 + CD71 − cells. For BMT mice, mice were infused with NHS sulfo-biotin 1 d before BMT.
Erythroid colony-forming assays. BFU-E (Stem Cell Technologies, M3436) and CFU-E (M3334) of bone marrow cells were plated according to the manufacturer's instructions and counted on days 10 and 3 of culture, respectively. Splenic stress BFU-E were assayed by plating 0.5 × 10 6 RBC-separated splenocytes in M3436 medium and enumerating after 5 d of culture. Endogenous (without npg
